In an all-cash transaction valued at €780 million (US$920 million), Asahi Kasei Corp. offered to buy Aicuris Anti-infective Cures AG, expanding its infectious disease portfolio with a marketed cytomegalovirus product and a herpes treatment nearing an NDA.
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral therapy. At the Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, the scientific community examined how the virus affects the brain, how the reservoir is established in the CNS, and which genetic, immunological or treatment-related factors influence cognitive health.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aktis, Alpha Tau, Alzecure, Amphastar, Haemonetics, Immedica, Intrabio, Larimar, Macrogenics, Mirus, Regeneron, Sanofi.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Biomarin, Chugai, Clinect, Epredia, Dartsbio, Five Discovery, Grünenthal, Invivyd, Microtransponder, Mindpeak, Miradx, Novartis, Novo Nordisk, Oncolytics, Pfizer, PHC, Porosome, Renew, Roche, Sarepta, Sciwind, Si-Bone, Smith+Nephew, Valinor.
Clinical updates for biopharma and med tech, including data readouts and publications: Abcuro, Arcus, Cadrenal, Fulcrum, Iovance, Keenova, Kyntra, Monte Rosa, Natera, Nicox, Novo Nordisk, Palvella, Protara, Quralis, Solascure, The United Laboratories, Viiv, Vir.
Biopharma and med-tech companies raising money in public or private financings, including: Abbott, Allurion, Alveus, Brainomix, Centauri, Exact Sciences, Salspera, Slate, Tandem Diabetes.
New hires and promotions in the biopharma and med-tech industries, including: Amber, Artiva, Boston Scientific, Diality, Helus, Human Continuum, Kyverna, Portal Access, Tectonic, Therna.
GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology.
United Therapeutics Corp.’s founder, chairman and CEO Martine Rothblatt disclosed during the company’s fourth-quarter earnings call Feb. 25 the “unsheathing of a category killer product” known as Tresmi, a drug-device formulation of treprostinil delivered via a soft mist inhaler.
RSS
